What's New

News

2024/11/01
Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.
2024/10/10
Annual update has been made to our Sustainability site.
2024/05/08
Received ‘AA’ for the first time in MSCI ESG Ratings
PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Integrated report
Sustainability